Reliable data on 5- and 10-year survival provide accurate estimates of 15-year survival in estrogen receptor-positive early-stage breast cancer
Tóm tắt
There are few studies of model-based survival projections using early empirical results for estimating long-term survival. Utilizing Early Breast Cancer Trialists’ Collaborative Group (EBCTCG) data, a Markov model was generated to compare empirical results with those modeled beyond the empirical result time horizon in estrogen receptor (ER)-positive early-stage breast cancer (ESBC). Modeling 15-year survival based on 5- and 10-year EBCTCG data resulted in an average error estimate in breast cancer mortality of 0.75% [range −0.83 to 2.19%]. Although modeling life expectancy differences ranged from an underestimate of −7.93% to an overestimate of 12.64%, over the span of 15 years this corresponded to a loss of 18 days or a gain of 40 days of life. Reliable early survival data may be used to generate models that accurately estimate 15-year survival in ER-positive ESBC. Whether early survival data can be employed over the lifetime horizon remains to be demonstrated.
Tài liệu tham khảo
Sackett DL, Haynes RB (1995) On the need for evidence-based medicine. Evid Based Med 1:5–6
Djulbegovic B, Hozo I, Lyman FH (2000) Linking evidence-based medicine therapeutic summary measures to clinical decision analysis. MedGenMed 2:E6
Gorlova OY, Kimmel M, Henschke C (2001) Modeling of long-term screening for lung carcinoma. Cancer 92:1531–1540. doi:10.1002/1097-0142(20010915)92:6<1531:AID-CNCR1479>3.0.CO;2-P
Fontana RS, Sanderson DR, Woolner LB et al (1986) Lung cancer screening: the Mayo program. J Occup Med 28:746–750. doi:10.1097/00043764-198608000-00038
Flehinger BJ, Kimmel M, Polyak T et al (1993) Screening for lung cancer. The Mayo Lung Project revisited. Cancer 72:1573–1580. doi:10.1002/1097-0142(19930901)72:5<1573:AID-CNCR2820720514>3.0.CO;2-9
Marcus PM, Bergstralh EJ, Fagerstrom RM et al (2000) Lung cancer mortality in the Mayo Lung Project: impact of extended follow-up. J Natl Cancer Inst 92:1308–1316. doi:10.1093/jnci/92.16.1308
Early Breast Cancer Trialists’ Collaborative Group (2005) Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials. Lancet 365:1687–1717. doi:10.1016/S0140-6736(05)66544-0
Chia S, Bryce C, Gelmon K (2005) The 2000 EBCTCG overview: a widening gap. Lancet 365:1665–1666. doi:10.1016/S0140-6736(05)66524-5
Weinstein MC, Siegel JE, Gold MR et al (1996) Recommendations of the panel on cost-effectiveness in health and medicine. JAMA 276:1253–1258. doi:10.1001/jama.276.15.1253
Spalding BJ (2008) Thumbs up for Avastin. Nat Biotechnol 26:365. doi:10.1038/nbt0408-365b
Miller K, Wang M, Gralow J et al (2007) Paclitaxel plus Bevacizumab versus Paclitaxel alone for metastatic breast cancer. N Engl J Med 357:2666–2676. doi:10.1056/NEJMoa072113
Bear HD, Anderson S, Smith RE et al (2006) Sequential preoperative or postoperative docetaxel added to preoperative doxorubicin plus cyclophosphamide for operable breast cancer: national surgical adjuvant breast and bowel project protocol B-27. J Clin Oncol 24:2019–2027. doi:10.1200/JCO.2005.04.1665
Rastogi P, Anderson SJ, Bear HD et al (2008) Preoperative chemotherapy: updates of national surgical adjuvant breast and bowel project protocols B-18 and B-27. J Clin Oncol 26:778–785. doi:10.1200/JCO.2007.15.0235